Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
13 August 2009 - 2:30PM
PR Newswire (US)
VANCOUVER, Aug. 13 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today announced
that it has received approval to begin marketing the Quill(TM) SRS
Polydioxanone (PDO), MONODERM(TM), Polypropylene and Nylon product
lines in Brazil. "We are very excited about the approval of the
Quill SRS product lines in Brazil, one of the largest surgical
markets in the world. Quill has been lauded in the U.S., Europe and
Canada for the efficiency it brings to wound closure. Now,
Brazilian patients and surgeons in plastics, orthopedics and
gynecology can benefit from it as well," said Dr. William Hunter,
President and CEO of Angiotech. The Quill SRS product lines include
two absorbable sutures - MONODERM and PDO, and two non-absorbable
sutures - Polypropylene and Nylon, and are approved for sale in the
U.S., Europe, and Canada. About the Quill(TM) Self-Retaining System
(SRS) Quill SRS represents a revolutionary technology in wound
closure made possible by bidirectional fixation within the wound.
Its patented design allows the surgeon to begin closure at the
midpoint of the wound and suture in two directions from the
midpoint. Barbs within the Quill SRS distribute tension across the
wound and eliminate the need for knots. Forward Looking Statements
-------------------------- Statements contained in this press
release that are not based on historical fact, including without
limitation statements containing the words "believes," "may,"
"plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 and constitute
"forward-looking information" within the meaning of applicable
Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to,
comments with respect to our objectives and priorities for the
remainder of 2009 and beyond, our strategies or future actions, our
targets, expectations for our financial condition and the results
of, or outlook for, our operations, research and development and
product and drug development. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be
materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Many such known risks, uncertainties and other factors
are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the
following: general economic and business conditions in the United
States, Canada and the other regions in which we operate; market
demand; technological changes that could impact our existing
products or our ability to develop and commercialize future
products; competition; existing governmental regulations and
changes in, or the failure to comply with, governmental
regulations; availability of financial reimbursement coverage from
governmental and third-party payers for products and related
treatments; adverse results or unexpected delays in pre-clinical
and clinical product development processes; adverse findings
related to the safety and/or efficacy of our products or products
sold by our partners; decisions, and the timing of decisions, made
by health regulatory agencies regarding approval of our technology
and products; the requirement for substantial funding to conduct
research and development, to expand manufacturing and
commercialization activities; and any other factors that may affect
our performance. In addition, our business is subject to certain
operating risks that may cause any results expressed or implied by
the forward-looking statements in this Quarterly Report on Form
10-Q to differ materially from our actual results. These operating
risks include: our ability to attract and retain qualified
personnel; our ability to successfully complete pre-clinical and
clinical development of our products; changes in our business
strategy or development plans; our failure to obtain patent
protection for discoveries; loss of patent protection resulting
from third-party challenges to our patents; commercialization
limitations imposed by patents owned or controlled by third
parties; our ability to obtain rights to technology from licensors;
liability for patent claims and other claims asserted against us;
our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products;
the ability to enter into, and to maintain, corporate alliances
relating to the development and commercialization of our technology
and products; market acceptance of our technology and products; our
ability to successfully manufacture, market and sell our products;
the availability of capital to finance our activities; our ability
to restructure and to service our debt obligations; and any other
factors referenced in our other filings with the applicable
Canadian securities regulatory authorities or the Securities and
Exchange Commission ("SEC"). For a more thorough discussion of the
risks associated with our business, see the "Risk Factors" section
in our annual report for the year ended December 31, 2008 filed
with the SEC on Form 10-K, and our quarterly report for the three
months ended June 30, 2009 filed with the SEC on Form 10-Q. Given
these uncertainties, assumptions and risk factors, investors are
cautioned not to place undue reliance on such forward-looking
statements. Except as required by law, we disclaim any obligation
to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained in
this press release to reflect future results, events or
developments. (C)2009 Angiotech Pharmaceuticals, Inc. All Rights
Reserved. Quill(TM) is a trademark of Quill Medical, Inc., a
wholly-owned subsidiary of Angiotech Pharmaceuticals, Inc. About
Angiotech Pharmaceuticals Angiotech Pharmaceuticals, Inc. is a
global specialty pharmaceutical and medical device company with
over 1,500 dedicated employees. Angiotech discovers, develops and
markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. DATASOURCE: Angiotech Pharmaceuticals,
Inc. CONTACT: DeDe Sheel, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4412,
Copyright